Clinical trial NCT02481050: Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Official title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: Eribulin Mesylate
Human Epidermal Growth Factor Receptor 2
Metastatic Breast Cancer
HER2-Negative
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
First posted: 2015-06-25
Enrollment: 58
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase 2, open-label, single arm, multicenter, 2-stage study of eribulin mesylate administered biweekly at 1.4 mg/m2 intravenously for the treatment of participants with HER2-negative metastatic breast cancer previously treated with 2 to 5 chemotherapy regimens.

Detailed description: This is a Phase 2, open-label, single arm, multicenter, 2-stage study of eribulin mesylate administered biweekly at 1.4 mg/m2 intravenously for the treatment of participants with HER2-negative metastatic breast cancer previously treated with 2 to 5 chemotherapy regimens. The study will be conducted in 3 Phases: a Pretreatment Phase (screening visit), a Treatment Phase (starting with Cycle 1 Day 1), and a Posttreatment Phase (End of treatment visit and survival follow up). Participants may remain on study drug as long as they demonstrate clinical benefit or until intercurrent illness, unacceptable toxicity, or disease progression occurs, until the participant withdraws consent, or death.

Eligibility criteria: Inclusion Criteria:

1. Histological or cytological adenocarcinoma of the breast.
2. Females, aged greater than or equal to 18 years at time of informed consent.
3. HER2-negative as determined by fluorescence in situ hybridization (FISH); or 0 or 1+ by immunohistochemistry (IHC) staining .
4. Participants with metastatic breast cancer who have received at least 2 and not more than 5 prior chemotherapy regimens.
5. Participants with at least one measurable lesion greater than or equal to 10 mm in the longest diameter for a non-lymph node or greater than or equal to 15 mm in the short-axis diameter for a lymph node as determined by investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
6. Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to 2.
7. Life expectancy of greater than or equal to 3 months.
8. Any neuropathy must recover to Grade less than or equal to 2 prior to enrollment.
9. Adequate renal function as evidenced by serum creatinine less than or equal to 1.5 mg/dL or calculated creatinine clearance greater than or equal to 50 mL/minute according to the Cockcroft and Gault formula.
10. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) greater than or equal to 1.5 X 10\^9/L, hemoglobin greater than or equal to 10.0 g/dL (can be corrected by growth factor or transfusion), and platelet count greater than or equal to 100 X 10\^9/L.
11. Adequate liver function as evidenced by total bilirubin less than or equal to 1.5 X upper limit of normal (ULN), alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 X ULN (less than or equal to 5 X ULN in the case of liver metastases), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.
12. Are willing and able to comply with all aspects of the treatment protocol.
13. Provide written informed consent.

Exclusion Criteria:

1. Previous treatment with eribulin.
2. Hypersensitivity to eribulin/excipients or halichondrin B or known intolerance of eribulin.
3. Current enrollment in another clinical study or used of any investigational drug or device within the past 28 days preceding informed consent.
4. Previous treatment with chemotherapy, radiation, biological, or targeted therapy within the last 2 weeks or 5 X half-life, whichever is longer, preceding informed consent.
5. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin (\[B-hCG\] test). A separate Baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
6. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
7. Females of childbearing potential who had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method \[such as condom plus diaphragm with spermicide\], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period or for 28 days after study drug discontinuation.

   Females who are currently abstinent and do not agree to use a double barrier method as described above or to refrain from sexual activity during the study period or for 28 days after study drug discontinuation.

   Females who are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study or for 28 days after study drug discontinuation.
8. Known central nervous system (CNS) disease, except for those participants with treated brain metastasis who are stable for at least 1 month with no evidence of progression or hemorrhage after treatment and no ongoing requirement for corticosteroids.
9. Known human immunodeficiency virus (HIV) positive.
10. Existing anticancer, therapy-related toxicities of Grades greater than or equal to 2, with the exception of alopecia.
11. A prior malignancy other than carcinoma in situ of the cervix, or nonmelanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated greater than 5 years previously with no subsequent evidence of recurrence.
12. Clinically significant cardiovascular impairment (congestive heart failure of New York Heart Association \[NYHA\] Classification greater than II, unstable angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia).
13. Clinically significant ECG abnormality, including a marked Baseline prolonged QT/QTc interval (ie, a repeated demonstration of a QTc interval greater than 500 milliseconds).
14. Pulmonary lymphangitic involvement that resulted in pulmonary dysfunction requiring active treatment, including the use of oxygen.
15. History of concomitant medical condition(s) that, in the opinion of the investigator, would compromise the participant's ability to safely complete the study.
16. The investigator's belief that the participant is medically unfit to receive eribulin or unsuitable for any other reason.

Primary outcomes:
measure: Objective Response Rate (ORR) by Investigator Assessment
timeFrame: From first dose of study drug until intercurrent illness, unacceptable toxicity, disease progression, or until the participant withdrew consent (approximately up to 2.3 years)
measure: Disease Control Rate (DCR) by Investigator Assessment
timeFrame: From first dose of study drug until intercurrent illness, unacceptable toxicity, disease progression, or until the participant withdrew consent (approximately up to 2.3 years)
Secondary outcomes:
measure: Progression-Free Survival (PFS) by Investigator Assessment
timeFrame: From first dose of study drug until intercurrent illness, unacceptable toxicity, disease progression, or until the participant withdrew consent (approximately up to 2.3 years)
measure: Overall Survival (OS)
timeFrame: From date of first dose of study drug administration until date of death from any cause (approximately up to 2.3 years)
measure: Feasibility Rate
timeFrame: Cycle 2 Day 28 and Cycle 4 Day 28 ( cycle length=28 days)
measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
timeFrame: From first dose of study drug (Baseline) up to 30 days after last dose of study drug (approximately up to 2.3 years)
Other outcomes:
Locations:
city: Denver
country: United States
facility: Facility #1
state: Colorado
city: Columbia
country: United States
facility: Facility #1
state: Maryland
city: Omaha
country: United States
facility: Facility #1
state: Nebraska
city: Albany
country: United States
facility: Facility #1
state: New York
city: Portland
country: United States
facility: Facility #1
state: Oregon
city: Dallas
country: United States
facility: Facility #1
state: Texas
city: Dallas
country: United States
facility: Facility #2
state: Texas
city: Houston
country: United States
facility: Facility #1
state: Texas
city: San Antonio
country: United States
facility: Facility #1
state: Texas
city: Tyler
country: United States
facility: Facility #1
state: Texas
city: Leesburg
country: United States
facility: Facility #1
state: Virginia
city: Winchester
country: United States
facility: Facility #1
state: Virginia
Study officials:
affiliation: Eisai Inc.
name: Sam Misir
role: STUDY_DIRECTOR
References: